This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2308849 (2023)
Siefker-Radtke, A. O. et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann. Oncol. https://doi.org/10.1016/j.annonc.2023.10.003 (2023)
Catto, J. W. F. et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann. Oncol. https://doi.org/10.1016/j.annonc.2023.09.3116 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. THOR provides new data on the efficacy of erdafitinib. Nat Rev Clin Oncol 21, 4 (2024). https://doi.org/10.1038/s41571-023-00836-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00836-0